Drug Trial Radar · NCT04353492
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
562
Actual
Start
Jul 14, 2020
Primary completion
Oct 9, 2024
Study completion Mar 11, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
Conditions
- Relapsing Multiple Sclerosis
Interventions
OfatumumabBiological
Subjects will receive ofatumumab injections in an autoinjector (AI) for subcutaneous administration containing 20 mg ofatumumab (50 mg/ml, 0.4 ml content)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR)Time frame: Up to 96 weeks from baseline
Locations
123 sites in 27 countries. Site status is shown where the registry gives one.
Fullerton Neuro and Headache Ctr
Fullerton, California
CU Anschutz Med Campus
Aurora, Colorado
Christiana Care Health Services
Newark, Delaware
Memorial Healthcare System
Hollywood, Florida
Homestead Assoc In Research Inc
Homestead, Florida
Neurology Associates PA
Maitland, Florida
UM Department Of Neurology
Miami, Florida
Negroski Neurology
Sarasota, Florida
Axiom Clinical Research of Florida
Tampa, Florida
University Of South Florida
Tampa, Florida
Premiere Research Institute
West Palm Beach, Florida
Atlanta Neuroscience Institute
Atlanta, Georgia
Georgia Neurology and Sleep Medicine Assoc
Suwanee, Georgia
Johns Hopkins Hospital
Baltimore, Maryland
Cleveland Clinic Foundation
Las Vegas, Nevada
University of New Mexico
Albuquerque, New Mexico
Five Towns Neuroscience Research
Woodmere, New York
Cleveland Clinic Foundation
Cleveland, Ohio
Columbus Neuroscience
Westerville, Ohio
Multiple Sclerosis Center of Excellence of OMRF
Oklahoma City, Oklahoma
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Baylor College of Medicine
Houston, Texas
Saturn Research Solutions LLC
Plano, Texas
INOVA Medical Group
Fairfax, Virginia
Ascension St Francis Center
Milwaukee, Wisconsin
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
New Lambton Heights, New South Wales, Australia
Novartis Investigative Site
Woolloongabba, Queensland, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Vienna, State of Vienna, Austria
Novartis Investigative Site
Linz, Upper Austria, Austria
Novartis Investigative Site
Bruges, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Edegem, Belgium
Novartis Investigative Site
Pleven, Bulgaria
Showing 40 of 123 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.